CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.981
NA - Nord America 9.595
AS - Asia 8.530
SA - Sud America 1.547
AF - Africa 263
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 30.953
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.319
RU - Federazione Russa 4.624
SG - Singapore 3.609
CN - Cina 2.295
BR - Brasile 1.269
IT - Italia 1.143
GB - Regno Unito 1.033
HK - Hong Kong 1.015
DE - Germania 888
FR - Francia 853
IE - Irlanda 709
SE - Svezia 584
VN - Vietnam 561
FI - Finlandia 474
KR - Corea 318
ID - Indonesia 194
NL - Olanda 180
CA - Canada 166
IN - India 115
AR - Argentina 100
PL - Polonia 94
AT - Austria 86
UA - Ucraina 83
JP - Giappone 78
MX - Messico 71
ES - Italia 66
BD - Bangladesh 55
ZA - Sudafrica 54
BJ - Benin 53
TG - Togo 51
TR - Turchia 43
EC - Ecuador 39
CO - Colombia 35
CZ - Repubblica Ceca 34
IQ - Iraq 29
VE - Venezuela 26
EG - Egitto 24
IR - Iran 24
TH - Thailandia 24
AU - Australia 23
PK - Pakistan 22
BE - Belgio 20
PY - Paraguay 20
UZ - Uzbekistan 20
MA - Marocco 19
LT - Lituania 18
UY - Uruguay 18
CL - Cile 17
PE - Perù 16
TN - Tunisia 16
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
AZ - Azerbaigian 11
MY - Malesia 11
KE - Kenya 10
SA - Arabia Saudita 10
IL - Israele 8
KG - Kirghizistan 8
NP - Nepal 8
EU - Europa 7
HR - Croazia 7
JO - Giordania 7
KZ - Kazakistan 7
LU - Lussemburgo 7
LV - Lettonia 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
AO - Angola 6
DZ - Algeria 6
GT - Guatemala 6
PH - Filippine 6
RO - Romania 6
TW - Taiwan 6
BG - Bulgaria 5
BO - Bolivia 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
HN - Honduras 5
KH - Cambogia 5
MK - Macedonia 5
PT - Portogallo 5
SN - Senegal 5
BY - Bielorussia 4
DK - Danimarca 4
JM - Giamaica 4
LA - Repubblica Popolare Democratica del Laos 4
PA - Panama 4
PS - Palestinian Territory 4
RS - Serbia 4
CU - Cuba 3
GR - Grecia 3
NO - Norvegia 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
EE - Estonia 2
ET - Etiopia 2
Totale 30.906
Salva come PNG Salva come JPEG
Città #
Dallas 1.790
Moscow 1.576
Singapore 1.335
Chandler 1.264
Hong Kong 1.004
Ashburn 768
Southend 738
Dublin 685
Beijing 471
Verona 370
Munich 343
Woodbridge 333
Jacksonville 301
Lawrence 267
Princeton 267
Los Angeles 226
New York 214
Ann Arbor 197
Ho Chi Minh City 194
Helsinki 191
Houston 189
Sindelfingen 185
Jakarta 153
Redondo Beach 150
Redmond 139
Buffalo 136
Jinan 136
Wilmington 135
The Dalles 130
São Paulo 129
Hanoi 106
Milan 102
London 99
Turku 91
Nanjing 84
Santa Clara 84
Shenyang 83
Columbus 81
Nuremberg 71
Tokyo 70
Toronto 64
Tianjin 63
Seattle 62
Hebei 61
Meda 58
Lappeenranta 56
Cotonou 53
Warsaw 53
Amsterdam 52
Chicago 52
Frankfurt am Main 52
Lomé 51
Montreal 46
Ningbo 45
Atlanta 44
Brooklyn 44
San Francisco 44
Seoul 44
Changsha 43
Guangzhou 43
Council Bluffs 42
Vienna 41
Rio de Janeiro 39
Zhengzhou 39
Denver 36
Johannesburg 36
Belo Horizonte 35
Hangzhou 35
Boston 33
Rome 33
Stockholm 33
Boardman 31
Haikou 31
Kent 31
Nanchang 31
Falkenstein 30
Taiyuan 30
Chennai 29
Dong Ket 29
Poplar 29
Da Nang 28
Washington 28
Taizhou 26
Redwood City 25
Curitiba 24
Orem 24
Jiaxing 23
Fuzhou 22
Shanghai 22
Ankara 21
Bangkok 21
Haiphong 21
Mexico City 21
Phoenix 21
Andover 20
Brno 20
Lanzhou 20
Tashkent 20
Brussels 19
Dongguan 18
Totale 17.034
Salva come PNG Salva come JPEG
Nome #
Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment 294
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 261
Genomic characterization of hepatoid tumors: context matters 217
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 203
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 194
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 179
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 177
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 173
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 171
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 162
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 162
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 160
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 158
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 156
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 155
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 154
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 154
Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature 152
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 152
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 151
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 151
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 150
A multimodal approach to cancer-related cachexia: from theory to practice 147
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 143
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 141
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 141
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 140
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 140
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 140
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 139
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 139
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 138
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 138
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 136
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 135
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 134
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 134
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 134
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 133
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 133
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 132
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 132
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 132
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 131
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 130
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 130
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 129
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 129
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 128
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 127
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 126
Loss of FGFR4 promotes the malignant phenotype of PDAC 125
Do immune checkpoint inhibitors need new studies methodology? 124
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 123
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 123
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 123
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 123
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 122
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 122
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 122
Sex differences in oncogenic mutational processes 121
Exercise levels and preferences in cancer patients: a cross-sectional study 120
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 120
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 119
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 118
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 117
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 117
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 117
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 116
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 116
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 116
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 116
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 115
Exercise and anemia in cancer patients: could make the difference? 115
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 115
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 114
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 113
Muscle derangement and alteration of the nutritional machinery in NSCLC 113
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer 112
Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin 112
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 111
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 111
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 111
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 111
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 110
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 109
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 109
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 109
Exercise oncology: It is time to make a change 109
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 109
A cross-sectional study exploring the perception of exercise oncology in the Italian population 108
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 107
Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients 107
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 107
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 107
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 106
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 106
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 106
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 106
A Journey through the Multifaceted Landscape of Prostate Cancer: from Bench to Bedside Studies 106
Totale 13.391
Salva come PNG Salva come JPEG
Categoria #
all - tutte 130.856
article - articoli 129.754
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 227
patent - brevetti 0
selected - selezionate 0
volume - volumi 875
Totale 261.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021585 0 0 0 0 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20257.962 438 354 332 1.393 349 302 437 439 1.112 629 730 1.447
2025/202611.970 1.501 1.258 2.031 3.586 3.594 0 0 0 0 0 0 0
Totale 31.473